49P: Phase II study of telomere-targeting agent THIO sequenced by cemiplimab in immune checkpoint inhibitor-resistant advanced NSCLC: Interleukin-6 as a potential predictive biomarker

作者：Tomasz Jankowski, Tibor Csőszi, László Urbán, Tünde Nagy, Rodryg Ramlau, Maria Cholakova, Nataliya P. Chilingirova, Andrzej Mruk, Szabolcs Soter, Krassimir Dimitrov Koynov, Marek Kotlarski, María Romina Girotti, I. Mender, Marcel Mitsunaga, Oleg Tudos, Matthew Failor, Bing Yao, V. Vitoc, S. Gryaznov, Victor Zaporojan · 发表于：Journal of Thoracic Oncology · 年份：2025 · DOI：10.1016/s1556-0864(25)00244-8 · 被引用次数：2 · 研究领域：Cancer Immunotherapy and Biomarkers、Nanoplatforms for cancer theranostics、Telomeres, Telomerase, and Senescence